BBIO

Bridgebio Pharma Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth↓ 0/10
  • Momentum↑ 8/10
Bridgebio Pharma sales and earnings growth
BBIO Growth
Low
  • Revenue Y/Y↑ 62.46%
  • EPS Y/Y↓ -74.27%
  • FCF Y/Y↓ -29.76%
Bridgebio Pharma gross and profit margin trends
BBIO Profitability
Good
  • Gross margin ↑ 95.80%
  • EPS margin↓ -225.30%
  • ROIC↓ -32.60%
Bridgebio Pharma net debt vs free cash flow
BBIO Risk
Great
  • Debt / Equity↓ -1.0
  • Debt / FCF↓ 2.1
  • Interest coverage↓ -5.6

Bridgebio Pharma stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗